Objective: We investigated the pathological effects of neoadjuvant chemotherapy based on the human epidermal growth factor receptor 2 in operable breast cancer. Methods: This prospective clinical study was a pilot involving 63 female patients. Before surgery, patients with tumors overexpressing human epidermal growth factor receptor 2 received four cycles of 60 mg/m 2 anthracycline and 600 mg/m 2 cyclophosphamide every 3 weeks, whereas those whose tumors did not overexpress human epidermal growth factor receptor 2 received four cycles of 75 mg/m 2 docetaxel and 600 mg/m 2 cyclophosphamide every 3 weeks. A quasi-pathological complete response (i.e. absence of invasive tumor or only focal residual tumor cells) was the primary endpoint, with compliance and predictors for each regimen as secondary endpoints. If a quasi-pathological complete response was not achieved, then crossover to the alternative treatment was recommended. Results: The quasi-pathological complete response rate was 36.5% (23 of 63) overall, 27.8% (5 of 18) for the anthracycline and cyclophosphamide regimen and 40.0% (18 of 45) for the docetaxel and cyclophosphamide regimen. Docetaxel and cyclophosphamide treatment induced a quasi-pathological complete response in most patients with triple-negative tumors (15 of 19). The relative dose intensity was 97.3% for the anthracycline and cyclophosphamide regimen and 96.6% for the docetaxel and cyclophosphamide regimen. Quasi-pathological complete response to the docetaxel and cyclophosphamide regimen was associated with low estrogen receptor and progesterone receptor expression and high MIB-1 and topoisomerase IIa expression, in univariate analyses, but only with low estrogen receptor expression in multivariate analysis. Conclusions: Selecting neoadjuvant chemotherapy regimens on the basis of individual human epidermal growth factor receptor 2 status improved efficacy, with docetaxel and cyclophosphamide treatment showing particular promise in tumors with the potential to be highly malignant.
INTRODUCTION
Adjuvant regimens using docetaxel and cyclophosphamide (TC) have been associated with superior overall survival rates compared with anthracycline and cyclophosphamide (AC) regimens in the treatment of breast cancer (1, 2) . Since these data were reported, regimens using non-anthracycline drugs with taxanes have become more common, although anthracycline-containing regimens are still the standard therapy. It has therefore become important to consider sensitivities to these two drugs in individual patients.
Several genes have been reported to be associated with sensitivity to anthracyclines and taxanes. For anthracyclines, these include human epidermal growth factor receptor 2 (HER2), estrogen receptor-a (ERa), p53, topoisomerase IIa (TopoIIa) and P-glycoprotein (3 -12) , and for taxanes, they include b-tubulin, cytochrome P450 3A4, Tau and thioredoxin (13) (14) (15) (16) (17) . However, their roles in predicting the clinical outcome of chemotherapy for breast cancer patients remain controversial.
Among these genes, HER2 is the most promising predictor of the chemosensitivity of breast cancers, as recent meta-analyses have revealed that the benefits of anthracyclines appear to be confined to patients with tumors overexpressing HER2 (3 -6) . In contrast, all the genes described above as associated with taxanes seem to be less promising predictors of sensitivity than HER2 for anthracyclines. On the basis of these results, we have conducted a pilot prospective clinical study of neoadjuvant chemotherapy using either AC or TC regimen depending upon the HER2 expression status of the tumors, to ask whether this individualization of the chemotherapy regimen improved its efficacy.
We also examined the association between the pathological response to each regimen and several other pathological factors. TopoIIa and class III b-tubulin have been of particular interest. Amplification of both the HER2 and TopoIIa genes appears to be associated with the effects of anthracyclines. On the basis of the mechanism of action of this class of drugs (12) and on previously published data (10, 11) , TopoIIa might be the optimal marker for predicting anthracycline sensitivity. With respect to docetaxel resistance, changes in the expression of b-tubulin isotypes are implicated as a possible mechanism, with high expression of class III b-tubulin reported to be associated with taxane resistance (14, 15) .
PATIENTS AND METHODS

PATIENT ELIGIBILITY
Patients eligible for this study were females with Stage II or III breast cancer (T !2 cm, N0 -3 and M0), including those with clinical stage T1N1M0 cancer. Patients staged as T1N0 were not eligible for inclusion. The other eligibility criteria were an Eastern Cooperative Oncology Group performance status of 0 and an age of !18 but ,75 years. Patients were ineligible if they were pregnant or nursing. All patients were diagnosed as having invasive breast cancer by a core-needle biopsy before treatment. The Institutional Review Board at Yokohama City University Medical Centre, Yokohama, Japan, approved the protocol on 15 Patients who showed Grade 4 non-hematological toxicity that progressed during chemotherapy, or whose treatment was delayed by more than 3 weeks for any toxicity-related reason were withdrawn from the study.
When a quasi-pathological complete response (QpCR) (as described below) was not achieved following the initial treatment, crossover to the alternative treatment was recommended. For non-QpCR cases after AC treatment, weekly paclitaxel was also added to the TC regimen. The study design is illustrated in Fig. 1 . All patients who underwent breastconserving surgery were given standard radiotherapy. Hormonal therapy was given at the discretion of the treating physician.
HISTOPATHOLOGICAL AND IMMUNOHISTOLOGICAL STUDIES OF PRE-TREATMENT SPECIMENS
The core-needle biopsy specimens from patients were fixed in 20% (w/v) formalin in phosphate-buffered saline and embedded in paraffin. Hematoxylin and eosin (H&E) sections of each block were prepared for histological diagnosis and used to determine the histological type and grade. AC was given to patients with breast tumors overexpressing HER2 (3þ), whereas other patients were given TC. In patients in whom a QpCR was not achieved, crossover treatment was recommended. AC, anthracycline and cyclophosphamide; HER2, human epidermal growth factor receptor 2; TC, docetaxel and cyclophosphamide; QpCR, quasi-pathological complete response.
Serial 3 -4 mm sections were mounted on silane-coated slides (Muto-glass, Tokyo, Japan) and dried at 378C overnight. Immunohistochemical staining was then performed using an automatic staining machine (Dako-autostainer; Dako, Kyoto, Japan). Slides were incubated at 958C for 40 min and de-paraffinized by four 5 min incubations in xylene, followed by 5 min each in 95%, 90% and 70% ethanol, and two 1 min washes in distilled water. Antigen retrieval was achieved by microwaving in citrate buffer (pH 6.0) for 40 min at 958C. The primary antibodies used in this study are listed in Table 1 . After treatment with endogenous peroxidase-blocking reagent (Dako), tissue sections were incubated with primary antibodies for 30 min and with secondary reagents (either Dako REAL TM EnVision TM Detection System, Dako or Ventana iVIEW DAB Universal Kit, Roche Diagnostics Inc., Tokyo Japan) for 30 min. Antibody labeling was visualized using 3,3 0 -diaminobenzidine (Dako) and slides were lightly counterstained with Mayer's hematoxylin.
The ER and progesterone receptor (PgR) status was evaluated using the Allred score (18) . Briefly, the proportion of positively stained tumor cells was estimated and assigned a score from 0 to 5 (0, negative; 1, 0 to ,1%; 2, 1 -10%; 3, 10-33%; 4, 33-66%; and 5, .66%) and an average intensity score was assigned for the positive tumor cells (0, none; 1, weak; 2, intermediate; and 3, strong). The final score in the range 0 -8 was the sum of the proportion and the intensity scores. The HER2 status was scored from 0 to 3þ using the scale outlined for the HercepTest (Dako) with only HER2 3þ tumors regarded as showing overexpression. Only unambiguous membrane staining was evaluated. For MIB-1, TopoIIa and p53, only unequivocal nuclear staining was considered as a positive result. Slides were scanned at low magnification to locate an area with the most evenly labeled tissue, where a minimum of 1000 tumor cells were scored at high power (Â350) and the percentage of labeled cells was calculated.
Immunostaining for class III b-tubulin was graded semi-quantitatively from the proportion of tumor cells with positive nuclear staining (0, 0%; 1, 0 -10%; and 2, .10%).
PATHOLOGICAL EVALUATION OF SURGICAL SPECIMENS
H&E-and keratin-stained slides were prepared from 5 mm tissue sections of the primary tumors. The effect of chemotherapy on the breast tumors was assessed blind by three board-certified pathologists (T.S., A.N. and K.K.), using a QpCR defined as the complete disappearance of invasive carcinoma in the breast and only focal tumor cells remaining in the stroma in the removed breast (19) .
STATISTICAL METHODS
The primary endpoint used in this study was the overall QpCR rate. The projected QpCR rate was estimated to be 18%, based on the results reported in previous neoadjuvant trials which included anthracycline (20, 21) . On this basis, the required sample size for this study was estimated to be 51 with 5% type I and 20% type II errors, and assuming overall QpCR rates of 10% and 35% for the null and alternative hypotheses, respectively. The rate of QpCR was compared between luminal B and HER2 subtypes in the AC group, and luminal A and triple-negative subtypes in the TC group, using Fisher's exact test. The secondary endpoints included compliance with the study protocol and the predictors of a QpCR (i.e. ER, PgR, p53, MIB-1, TopoIIa and class III b-tubulin expression) for each regimen. The MannWhitney U-test was used to compare gene expression between the two groups. For each marker, tumors were divided into high-and low-expression groups; for ER and PgR, tumors with Allred scores of 0 -3 were considered low, and 4 -8 high. For p53, MIB-1, TopoIIa and class III b-tubulin, the mean values were used as the cut-off points to divide the high-and low-expression groups. Individual analyses were carried out for each predictor and multivariate analysis by logistic regression was also performed, using the Statistical Package for Social Science (SPSS) software.
RESULTS
In total, 63 patients were enrolled in this trial between February 2007 and March 2009. On the basis of their HER2 status, 18 patients were assigned to AC treatment and 45 were assigned to TC treatment. Table 2 shows the baseline characteristics of the patients. In total, 26 (41.3%) of the patients had Stage III disease. The patient characteristics were well balanced, with the exception of HER2 expression. None of the patients dropped out during neoadjuvant chemotherapy, and so the pathological responses were evaluated in all of the patients.
PATHOLOGICAL TUMOR RESPONSE
The overall pathological breast tumor responses and the responses for each treatment regimen are shown in Fig. 2 . In total, 23 of 63 (36.5%) patients showed a QpCR. QpCRs were attained by 5 of 18 (27.8%) patients who received AC Table 3 shows the expression profiles of five genes in the biopsies before treatment from the two groups treated with AC or TC. There were no statistical differences in the expression of these five genes between the two groups. Individual analysis of these genes showed a statistically significant association between a QpCR to the TC regimen and ER, PgR, TopoIIa and MIB-1 expression, but no associations were found with the AC regimen. Multivariate analysis for these five predictors showed that only ER expression remained statistically significant as a predictor of QpCR to the TC regimen (Table 4) .
DISCUSSION
This study has shown that planning neoadjuvant chemotherapy on the basis of HER2 status can improve the pathological responses to either anthracycline-or docetaxel-containing regimens, providing a paradigm for individualized treatment for breast cancer patients. This study has also shown that TC Figure 2 . Pathological responses for all breast cancer patients and for the AC-or TC-treated groups. QpCRs were more frequent in the TC group than in the AC group. was a particularly effective treatment for tumors of potentially high malignancy, such as the triple-negative subtype. The overall QpCR rate in this study was 36.5%. Previous studies have reported QpCR rates for combined therapies with anthracyclines and taxanes of between 23.0% and 25.9% (22 -24) . It is generally accepted that combined therapy with anthracycline and taxane provides better results than using either drug alone (25) . However, both these drugs are not always required to treat all patients, as the sensitivity to each drug varies in different individuals. It could be of benefit to use one or other of these drugs, provided that a sufficient pathological response can be achieved. Neoadjuvant therapy allows us to choose which drugs a tumor is likely to be most sensitive to, with the possibility of following up with a different regimen if the initial therapy does not achieve an adequate response.
In the AC-treated group, the rate of QpCR (27.8%) was better than the rate reported for anthracycline-containing regimen (20, 21) and comparable to the rates seen with combined treatments with taxane (22 -24) . This probably results from selectively administering AC to cases showing HER2 overexpression. This suggests that HER2 overexpression is at present the most promising predictor for the efficacy of anthracyclines. Other genes examined, including TopoIIa, were not found to be associated with the efficacy of the AC regimen.
The TC regimen produced a higher QpCR rate (40.0%) than the AC regimen (27.8%). However, comparing the efficacy of the two regimens directly is not very useful, because the subtypes of breast cancers treated were different in the two groups. AC treatment was given to patients with luminal B and HER2 tumors, whereas TC was administered to those with luminal A and triple-negative tumors. TC therapy was unexpectedly effective in patients with triple-negative breast (2) . However, our current results do not necessarily contradict these data, as a subanalysis of the 9735 trial revealed that the TC regimen was superior to the AC regimen for ER2 and HER22 tumors compared with ERþ and HER2þ tumors. This supports our results, showing that the triple-negative subtype might be the best target for TC treatment. The positive correlation seen with MIB-1 and TopoIIa expression also suggested that the TC regimen might be effective in breast cancer patients with a relatively high malignancy risk.
Triple-negative breast cancer subtypes are generally more sensitive to anti-cancer agents than non-triple-negative subtypes (26) . However, chemotherapy using taxane alone seems to be less promising than combined regimens that include anthracycline for treating the triple-negative subtype (27) . This is probably because agents that damage DNA are theoretically more effective for treating triple-negative breast cancers than other types of drug (28) . In this study, TC was unexpectedly effective against triple-negative tumors, showing a high QpCR rate, compared with combined regimens such as 5-fluorouracil, epirubicin and cyclophosphamide (FEC100) followed by 75 mg/m 2 docetaxel (QpCR: 25%) (24) . We speculated that a combination of cyclophosphamide and docetaxel might offer improved efficacy, as synergy between these drugs had been observed in preclinical tests (29) .
Although the TC regimen produced more frequent cases of febrile neutropenia than had been reported in the US oncology research trial 9735 (1), the treatment was feasible and effective, especially for ER2 subtypes. We have therefore launched a randomized Phase II study to compare six cycles of TC treatment with the standard FEC100 regime followed by 100 mg/m 2 of docetaxel for hormone receptor-negative breast cancers at the neoadjuvant setting.
